VYNE Therapeutics (Nasdaq:VYNE) - Aandelenkoers, Nieuws & Analyse

VYNE Overzicht aandelen

VYNE Therapeutics Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van gepatenteerde geneesmiddelen voor de behandeling van immuno-inflammatoire aandoeningen.

Over het bedrijf

VYNE fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 88.69% per year

Earnings have grown 35.3% per year over the past 5 years

Analysts in good agreement that stock price will rise by 110.7%

Risicoanalyse

Earnings are forecast to decline by an average of 16% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($486K)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 meer risico

VYNE Therapeutics Inc. Concurrenten

Landos Biopharma

NasdaqCM:LABP

US$71.7m

ALT5 Sigma

NasdaqCM:ALTS

US$30.5m

Grace Therapeutics

NasdaqCM:GRCE

US$31.4m

Milestone Pharmaceuticals

NasdaqGS:MIST

US$95.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor VYNE Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$2.65
52 Week Hoogtepunt	US$4.48
52 Week Laag	US$1.57
Bèta	1.46
11 maand verandering	40.21%
3 maanden verandering	49.72%
1 Jaar Verandering	-18.71%
33 jaar verandering	-89.17%
5 jaar verandering	n/a
Verandering sinds IPO	-99.02%

Recent nieuws en updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Oct 09

Recent updates

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

VYNE Therapeutics closes capital raise of $50M

Jan 29

Rendement voor aandeelhouders

	VYNE	US Pharmaceuticals	US Markt
7D	-6.7%	-3.7%	-1.6%
1Y	-18.7%	17.2%	30.8%

Rendement versus industrie: VYNE underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.

Rendement versus markt: VYNE underperformed the US Market which returned 30.6% over the past year.

Prijsvolatiliteit

Is VYNE's price volatile compared to industry and market?
VYNE volatility
VYNE Average Weekly Movement	9.1%
Pharmaceuticals Industry Average Movement	9.3%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: VYNE has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: VYNE's weekly volatility (9%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	10	Dave Domzalski	www.vynetherapeutics.com

VYNE Therapeutics Inc, een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van gepatenteerde geneesmiddelen voor de behandeling van ontstekingsziekten. Het belangrijkste product van het bedrijf is VYN201, een lokaal toegediende pan-bromodomein- en extra-terminale (BET) remmer voor de behandeling van ziekten waarbij meerdere, uiteenlopende ontstekingscelsignaleringsroutes betrokken zijn met een lage systemische blootstelling. Het ontwikkelt ook VYN202, een BD2-selectieve orale kleine molecule BET-remmer voor de behandeling van immuno-inflammatoire indicaties.

VYNE Therapeutics Inc. Samenvatting

Hoe verhouden de winst en inkomsten van VYNE Therapeutics zich tot de beurswaarde?
VYNE fundamentele statistieken
Marktkapitalisatie	US$39.09m
Inkomsten(TTM)	-US$28.01m
Inkomsten(TTM)	US$486.00k

80.4x

P/S-verhouding

-1.4x

Koers/Winstverhouding

Is VYNE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VYNE resultatenrekening (TTM)
Inkomsten	US$486.00k
Kosten van inkomsten	US$0
Brutowinst	US$486.00k
Overige uitgaven	US$28.49m
Inkomsten	-US$28.01m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.90
Brutomarge	100.00%
Nettowinstmarge	-5,762.76%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde VYNE op de lange termijn?

Bekijk historische prestaties en vergelijking

VYNE Overzicht aandelen

Beloningen

Risicoanalyse

VYNE Therapeutics Inc. Concurrenten

NasdaqCM:LABP

US$71.7m

NasdaqCM:ALTS

US$30.5m

NasdaqCM:GRCE

US$31.4m

NasdaqGS:MIST

US$95.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

Recent updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for the Treatment of Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Price target increased to US$5.80

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely